Drug Profile
Chlorhexidine/recombinant epidermal growth factor/silver sulfadiazine
Alternative Names: Chlorhexidine/silver sulfadiazine/recombinant epidermal growth factor; Recombinant epidermal growth factor/chlorhexidine/silver sulfadiazine; Recombinant epidermal growth factor/silver sulfadiazine/chlorhexidine; rhEGF/silver sulfadiazine/chlorhexidine gluconate; Silver sulfadiazine/chlorhexidine/recombinant epidermal growth factor; Silver sulfadiazine/recombinant epidermal growth factor/chlorhexidine; SLVRGENLatest Information Update: 20 Mar 2014
Price :
$50
*
At a glance
- Originator Bharat Biotech
- Class Antibacterials; Antiseptics; Growth factors; Heavy metals; Skin disorder therapies; Sulfonamides
- Mechanism of Action Epidermal growth factor receptor agonists; Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Burns
Most Recent Events
- 31 Dec 2010 Launched for Burns in India (Topical) prior to December 2010
- 31 Dec 2010 Registered for Burns in India (Topical) prior to December 2010